Business
Statement re share price, update on EpiSwitch PSE
Oxford BioDynamics Plc has issued a statement addressing recent share price movements, clarifying that the UK National Screening Committee's draft recommendation on prostate cancer screening has no direct impact on the company or its EpiSwitch PSE test. The company highlighted that sales of its PSE test in the US and to private healthcare in the UK have shown consistent growth, with six consecutive record months reported from June to November 2025, indicating ongoing commercial success. Disclaimer*
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n\n \n \n3 December 2025 \n\nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\nStatement re share price movement, update on EpiSwitch PSE\nThe Board of Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, notes the recent movement in the Company's share price following the publication on 28 November of the UK National Screening Committee's (NSC) draft recommendation in respect of prostate cancer screening.\nThe NSC's draft recommendation has no direct impact on OBD or the Group's EpiSwitch PSE test. PSE test sales in the US and to private healthcare in the UK have continued to increase, with six successive record months reported from June to November 2025.\n-Ends-\nFor further details please contact:\n\n\n\n\n Oxford BioDynamics Plc\n\n\nTel: +44 (0)1865 518910\n\n\n\n\nIain Ross, Executive Chairman\nPaul Stockdale, CFO\n\n\n\n\n\n\n\nShore Capital - Nominated Adviser and Broker\n\n\nTel: +44 (0)20 7408 4090\n\n\n\n\nStephane Auton / Lucy Bowden\n\n\n\n\n\n\n\nOAK Securities - Joint Broker\n\n\nTel: +44 (0)20 3973 3678\n\n\n\n\nMatthew Clarke / Tim Dainton / Calvin Man\n\n\n\n\n\n\n\nCamarco - Financial PR\n\n\nTel: +44 (0)20 3757 4980\n\n\n\n\nMarc Cohen / Tilly Butcher / Fergus Young\n\n\[email protected]\n\n\n\n\n \nNotes to Editors\nAbout Oxford BioDynamics Plc\nOxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.\nCurrently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.\nThe tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose ...